Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sera Prognostics Inc SERA

Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.


NDAQ:SERA - Post by User

Bullboard Posts
Next >>
Post by AviseAnalyticson Mar 08, 2022 10:33am
46 Views
Post# 34495017

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

$SERA $MYGN $PGNY $MYOV
 
8th March celebrates the cultural, political and socioeconomic achievements of women from different strata and geographies across the globe. Femtech, a category that leverages technology to address issues related to women’s health, is poised to become a $50 billion dollar industry by year 2025, according to estimates by Frost & Sullivan.
 
There are many companies in the clinical diagnostics, biotechnology, biopharmaceutical and medical device space that are dedicated to improving the lives of women, by addressing health issues such as cancers, endometritis and fertility management among others. We take a look at some of them that are at the forefront of innovation in women’s health:
 
Read on to know more:[/url

]https://www.aviseanalytics.com/4-stocks-opening-new-frontiers-in-womens-health/

Bullboard Posts
Next >>